Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvementSimona Soverini, Giovanni Martinelli, Gian Matteo Rigolin et al.|Cancer|2013Cited by 143
Cardiovascular Toxicities of Immune Therapies for Cancer – A Scientific Statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-OncologyCarlo G. Tocchetti, Teresa López‐Fernández, Alexander R. Lyon et al.|European Journal of Heart Failure|2024Cited by 64
SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome–positive cells derived from patients with chronic myeloid leukemiaNicola Esposito, Fabrizio Pane|Blood|2011Cited by 47
Diagnostic capabilities, clinical features, and longitudinal <scp><i>UBA1</i></scp> clonal dynamics of a nationwide <scp>VEXAS</scp> cohortCarmelo Gurnari, Maria Teresa Voso, Maria Rosaria Pascale et al.|American Journal of Hematology|2023Cited by 43
Methodology and clinical utility of longitudinal <scp><i>UBA1</i></scp> tracking in <scp>VEXAS</scp> syndromeCarmelo Gurnari, Maria Teresa Voso, Elisa Galossi et al.|British Journal of Haematology|2024Cited by 10